Advanced search

Vol 14, No 5 (2018)
Review paper
Published online: 2019-02-15

open access

View PDF Download PDF file
Page views 2278
Article views/downloads 992
Get Citation

Connect on Social Media

Connect on Social Media

Anti-cancer agents and endothelium

Renata Pacholczak12, Jerzy Dropiński3, Jerzy Walocha1, Jacek Musiał3
DOI: 10.5603/OCP.2018.0032
Oncol Clin Pract 2018;14(5):249-256.

Abstract

Recent advances in oncology have improved the treatment outcomes and life expectancy of cancer patients; therefore, late effects of oncological treatment are of high clinical importance. Recent studies have shown that cardiovascular events are among the leading causes of premature morbidity in cancer survivors. Cardiotoxicity of some chemotherapeutic agents have been already confirmed; however, this issue seems to be more complex. Endothelium dysfunction is one of the first recognisable signs of atherosclerosis, which occurs long before the development of overt cardiovascular disease. Thus, it could be considered as an initial step, leading to increased risk of cardiovascular events. This process is not easy to recognise; however, there are some laboratory tests and imagining techniques that provide an insight into the progression of endothelial dysfunction. In this review we discuss the influence of oncological treatment on endothelium, according to the hypothesis that it increases cardiovascular morbidity and mortality in cancer survivors. Additionally, we present diagnostic and therapeutic measures that could reduce cardiovascular risk in cancer patients.

Keywords: endotheliumcancerchemotherapeutic agentsradiotherapy

Article available in PDF format

View PDF Download PDF file

References

  1. Mulrooney DA, Blaes AH, Duprez D. Vascular injury in cancer survivors. J Cardiovasc Transl Res. 2012; 5(3): 287–295.
    CrossRefPubMed
  2. Hooning MJ, Botma A, Aleman BMP, et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst. 2007; 99(5): 365–375.
    CrossRefPubMed
  3. Jang WJ, Choi DY, Jeon IS. Vascular endothelial dysfunction after anthracyclines treatment in children with acute lymphoblastic leukemia. Korean J Pediatr. 2013; 56(3): 130–134.
    CrossRefPubMed
  4. Jenei Z, Bárdi E, Magyar MT, et al. Anthracycline causes impaired vascular endothelial function and aortic stiffness in long term survivors of childhood cancer. Pathol Oncol Res. 2013; 19(3): 375–383.
    CrossRefPubMed
  5. Reilley MJ, Jacobs LA, Vaughn DJ, et al. Cardiovascular risk in long-term survivors of testicular cancer. Cancer. 2008; 112(9): 1949–1953.
    CrossRefPubMed
  6. Schimmel KJM, Richel DJ, van den Brink RBA, et al. Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev. 2004; 30(2): 181–191.
    CrossRefPubMed
  7. Yeh ETH, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004; 109(25): 3122–3131.
    CrossRefPubMed
  8. Khouri MG, Douglas PS, Mackey JR, et al. Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues. Circulation. 2012; 126(23): 2749–2763.
    CrossRefPubMed
  9. Haykowsky MJ, Mackey JR, Thompson RB, et al. Cardiovascular risk profile of patients with HER2/neu-positive breast cancer treated with anthracycline-taxane-containing adjuvant chemotherapy and/or trastuzumab. Cancer Epidemiol Biomarkers Prev. 2007; 16(5): 1026–1031.
    CrossRefPubMed
  10. Brunner H, Cockcroft JR, Deanfield J, et al. Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens. 2005; 23(2): 233–246.
    CrossRefPubMed
  11. Widlansky ME, Gokce N, Keaney JF, et al. The clinical implications of endothelial dysfunction. J Am Coll Cardiol. 2003; 42(7): 1149–1160.
    CrossRefPubMed
  12. Govers R, Rabelink TJ. Cellular regulation of endothelial nitric oxide synthase. Am J Physiol Renal Physiol. 2001; 280(2): F193–F206.
    CrossRefPubMed
  13. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation. 2007; 115(10): 1285–1295.
    CrossRefPubMed
  14. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). European Heart Journal. 2007; 28(19): 2375–2414.
    CrossRef
  15. Liao JK. Linking endothelial dysfunction with endothelial cell activation. J Clin Invest. 2013; 123(2): 540–541.
    CrossRefPubMed
  16. Erdbruegger U, Haubitz M, Woywodt A. Circulating endothelial cells: a novel marker of endothelial damage. Clin Chim Acta. 2006; 373(1-2): 17–26.
    CrossRefPubMed
  17. Meroni PL, Borghi MO, Raschi E, et al. Inflammatory response and the endothelium. Thromb Res. 2004; 114(5-6): 329–334.
    CrossRefPubMed
  18. Verma S, Buchanan MR, Anderson TJ. Endothelial function testing as a biomarker of vascular disease. Circulation. 2003; 108(17): 2054–2059.
    CrossRefPubMed
  19. Landim MB, Casella Filho A, Chagas AC. Asymmetric dimethylarginine (ADMA) and endothelial dysfunction: implications for atherogenesis. Clinics (Sao Paulo). 2009; 64(5): 471–478.
    CrossRefPubMed
  20. Böger RH, Vallance P, Cooke JP. Asymmetric dimethylarginine (ADMA): a key regulator of nitric oxide synthase. Atheroscler Suppl. 2003; 4(4): 1–3.
    CrossRefPubMed
  21. Healy B, Ojrio C. Endothelial Cell Dysfunction : An Emerging Endocrinopathy Linked To Coronary Disease. JACC. 1990; 16(2): 7–8.
  22. Harris RA, Nishiyama SK, Wray DW, et al. Ultrasound assessment of flow-mediated dilation. Hypertension. 2010; 55(5): 1075–1085.
    CrossRefPubMed
  23. Morganti M, Carpi A, Nicolini A, et al. Atherosclerosis and cancer: common pathways on the vascular endothelium. Biomed Pharmacother. 2002; 56(7): 317–324.
    CrossRefPubMed
  24. Kebers F, Lewalle JM, Desreux J, et al. Induction of endothelial cell apoptosis by solid tumor cells. Exp Cell Res. 1998; 240(2): 197–205.
    CrossRefPubMed
  25. de Vos FY, Willemse PHB, de Vries EGE, et al. Endothelial cell effects of cytotoxics: balance between desired and unwanted effects. Cancer Treat Rev. 2004; 30(6): 495–513.
    CrossRefPubMed
  26. Minotti G, Menna P, Salvatorelli E, et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004; 56(2): 185–229.
    CrossRefPubMed
  27. Duquaine D, Hirsch GA, Chakrabarti A, et al. Rapid-onset endothelial dysfunction with adriamycin: evidence for a dysfunctional nitric oxide synthase. Vasc Med. 2003; 8(2): 101–107.
    CrossRefPubMed
  28. Vásquez-Vivar J, Martasek P, Hogg N, et al. Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin. Biochemistry. 1997; 36(38): 11293–11297.
    CrossRefPubMed
  29. Rajagopalan S, Politi PM, Sinha BK, et al. Adriamycin-induced free radical formation in the perfused rat heart: implications for cardiotoxicity. Cancer Res. 1988; 48(17): 4766–4769.
    PubMed
  30. Volkova M, Russell R. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev. 2011; 7(4): 214–220.
    CrossRefPubMed
  31. Murata T, Yamawaki H, Yoshimoto R, et al. Chronic effect of doxorubicin on vascular endothelium assessed by organ culture study. Life Sci. 2001; 69(22): 2685–2695.
    CrossRefPubMed
  32. Wu S, Ko YS, Teng MS, et al. Adriamycin-induced cardiomyocyte and endothelial cell apoptosis: in vitro and in vivo studies. J Mol Cell Cardiol. 2002; 34(12): 1595–1607.
    CrossRefPubMed
  33. Majzner K, Wojcik T, Szafraniec E, et al. Nuclear accumulation of anthracyclines in the endothelium studied by bimodal imaging: fluorescence and Raman microscopy. Analyst. 2015; 140(7): 2302–2310.
    CrossRefPubMed
  34. Lundman P, Eriksson MJ, Stühlinger M, et al. Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J Am Coll Cardiol. 2001; 38(1): 111–116.
    CrossRefPubMed
  35. Chow AY, Chin C, Dahl G, et al. Anthracyclines cause endothelial injury in pediatric cancer patients: a pilot study. J Clin Oncol. 2006; 24(6): 925–928.
    CrossRefPubMed
  36. Ryberg M. Cardiovascular toxicities of biological therapies. Semin Oncol. 2013; 40(2): 168–177.
    CrossRefPubMed
  37. Hotchkiss KA, Ashton AW, Mahmood R, et al. Inhibition of Endothelial Cell Function in Vitro and Angiogenesis in Vivo by Docetaxel ( Taxotere ): Association with Impaired Repositioning of the Microtubule Organizing Center 1 Supported by grants from the National Cancer P01-CA13330 ), Aventis Pharmac. 2002;1(November):1191-1200.
  38. Morbidelli L, Donnini S, Ziche M. Targeting endothelial cell metabolism for cardio-protection from the toxicity of antitumor agents. Cardio-Oncology. 2016; 2(1).
    CrossRef
  39. Milross CG, Mason KA, Hunter NR, et al. Enhancement of tumor radioresponse of a murine mammary carcinoma by paclitaxel. Cancer Res. 1994; 54(13): 3506–3510.
    PubMed
  40. Verweij J, Clavel M, Chevalier B. Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. Ann Oncol. 1994; 5(6): 495–505.
    PubMed
  41. Salvatorelli E, Menna P, Cascegna S, et al. Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: implications for cardiotoxicity of doxorubicin-taxane chemotherapies. J Pharmacol Exp Ther. 2006; 318(1): 424–433.
    CrossRefPubMed
  42. Vassilakopoulou M, Mountzios G, Papamechael C, et al. Paclitaxel chemotherapy and vascular toxicity as assessed by flow-mediated and nitrate-mediated vasodilatation. Vascul Pharmacol. 2010; 53(3-4): 115–121.
    CrossRefPubMed
  43. Belotti D, Vergani V, Drudis T, et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res. 1996; 2(11): 1843–1849.
    PubMed
  44. Gamble GE, Tyrrell P. Acute stroke following cisplatin therapy. Clinical Oncology. 1998; 10(4): 274–275.
    CrossRefPubMed
  45. Içli F, Karaoğuz H, Dinçol D, et al. Severe vascular toxicity associated with cisplatin-based chemotherapy. Cancer. 1993; 72(2): 587–593.
    PubMed
  46. Czaykowski PM, Moore MJ, Tannock IF. High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy. J Urol. 1998; 160(6 Pt 1): 2021–2024.
    CrossRefPubMed
  47. Shi Y, Inoue S, Shinozaki R, et al. Release of cytokines from human umbilical vein endothelial cells treated with platinum compounds in vitro. Jpn J Cancer Res. 1998; 89(7): 757–767.
    CrossRefPubMed
  48. Gietema JA, Meinardi MT, Messerschmidt J, et al. Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer. Lancet. 2000; 355(9209): 1075–1076.
    CrossRefPubMed
  49. Meinardi MT, Gietema DJ, van Veldhuisen† W. Long-term chemotherapy-related cardiovascular morbidity. Cancer Treat Rev. 2000; 26(1): 269–286.
  50. Nuver J, De Haas EC, Van Zweeden M, et al. Vascular damage in testicular cancer patients: a study on endothelial activation by bleomycin and cisplatin in vitro. Oncol Rep. 2010; 23(1): 247–253.
    CrossRefPubMed
  51. Dieckmann KP, Struss WJ, Budde U. Evidence for acute vascular toxicity of cisplatin-based chemotherapy in patients with germ cell tumour. Anticancer Res. 2011; 31(12): 4501–4505.
    PubMed
  52. Nuver J, Smit AJ, van der Meer J, et al. Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. J Clin Oncol. 2005; 23(36): 9130–9137.
    CrossRefPubMed
  53. Togna GI, Togna AR, Franconi M, et al. Cisplatin triggers platelet activation. Thromb Res. 2000; 99(5): 503–509.
    CrossRefPubMed
  54. Bonita R, Pradhan R. Cardiovascular toxicities of cancer chemotherapy. Semin Oncol. 2013; 40(2): 156–167.
    CrossRefPubMed
  55. Taniguchi I. Clinical Significance of Cyclophosphamide-induced Cardiotoxicity. Intern Med. 2005; 44(2): 89–90.
    CrossRef
  56. Colleoni M, Rocca A, Sandri MT, et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol. 2002; 13(1): 73–80.
    CrossRefPubMed
  57. Folkman J. New perspectives in clinical oncology from angiogenesis research. Eur J Cancer. 1996; 32A(14): 2534–2539.
    CrossRefPubMed
  58. Kachel DL, Martin WJ. Cyclophosphamide-induced lung toxicity: mechanism of endothelial cell injury. J Pharmacol Exp Ther. 1994; 268(1): 42–46.
    PubMed
  59. Bocci G, Nicolaou K, Kerbel R. Protracted Low-Dose Effects on Human Endothelial Cell Proliferation and Survival in Vitro Reveal a Selective Antiangiogenic Window for Various Chemotherapeutic Drugs. Cancer Res. 2002:6938-6943. http://cancerres.aacrjournals.org/cgi/content/abstract/62/23/6938%5Cnpapers2://publication/uuid/024740E1-87EE-43D7-AC32-90260C1B9C25.
  60. Cwikiel M, Eskilsson J, Wieslander JB, et al. The appearance of endothelium in small arteries after treatment with 5-fluorouracil. An electron microscopic study of late effects in rabbits. Scanning Microsc. 1996; 10(3): 805–18; discussion 819.
    PubMed
  61. Cwikiel M, Zhang B, Eskilsson J, et al. The influence of 5-fluorouracil on the endothelium in small arteries. An electron microscopic study in rabbits. Scanning Microsc. 1995; 9(2): 561–576.
    PubMed
  62. Cwikiel M, Eskilsson J, Albertsson M, et al. The influence of 5-fluorouracil and methotrexate on vascular endothelium. An experimental study using endothelial cells in the culture. Ann Oncol. 1996; 7(7): 731–737.
    CrossRefPubMed
  63. Focaccetti C, Bruno A, Magnani E, et al. Effects of 5-fluorouracil on morphology, cell cycle, proliferation, apoptosis, autophagy and ROS production in endothelial cells and cardiomyocytes. PLoS One. 2015; 10(2): e0115686.
    CrossRefPubMed
  64. Kuzel T, Esparaz B, Green D, et al. Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin. Cancer. 1990; 65(4): 885–889, doi: 10.1002/1097-0142(19900215)65:4<885::aid-cncr2820650410>3.0.co;2-h.
    PubMed
  65. Kim SM, Kwak CH, Lee B, et al. A case of severe coronary spasm associated with 5-fluorouracil chemotherapy. Korean J Intern Med. 2012; 27(3): 342–345.
    CrossRefPubMed
  66. Mosseri M, Fingert HJ, Varticovski L, et al. In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle. Cancer Res. 1993; 53(13): 3028–3033.
    PubMed
  67. Südhoff T, Enderle MD, Pahlke M, et al. 5-Fluorouracil induces arterial vasocontractions. Ann Oncol. 2004; 15(4): 661–664.
    CrossRefPubMed
  68. Berardi R, Caramanti M, Savini A, et al. State of the art for cardiotoxicity due to chemotherapy and to targeted therapies: a literature review. Crit Rev Oncol Hematol. 2013; 88(1): 75–86.
    CrossRefPubMed
  69. Choueiri TK, Mayer EL, Je Y, et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol. 2011; 29(6): 632–638.
    CrossRefPubMed
  70. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007; 96(12): 1788–1795.
    CrossRefPubMed
  71. Thiele H, Zeymer U, Neumann FJ, et al. Intraaortic Balloon Support for Myocardial Infarction with Cardiogenic Shock. New England Journal of Medicine. 2012; 367(14): 1287–1296.
    CrossRef
  72. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007; 99(16): 1232–1239.
    CrossRefPubMed
  73. Veronese ML, Mosenkis A, Flaherty KT, et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol. 2006; 24(9): 1363–1369.
    CrossRefPubMed
  74. Mir O, Mouthon L, Alexandre J, et al. Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome? J Natl Cancer Inst. 2007; 99(1): 85–86.
    CrossRefPubMed
  75. Thijs AMJ, van Herpen CML, Sweep FC, et al. Role of endogenous vascular endothelial growth factor in endothelium-dependent vasodilation in humans. Hypertension. 2013; 61(5): 1060–1065.
    CrossRefPubMed
  76. Mourad JJ, des Guetz G, Debbabi H, et al. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol. 2008; 19(5): 927–934.
    CrossRefPubMed
  77. Thijs AMJ, van Herpen CML, Verweij V, et al. Impaired endothelium-dependent vasodilation does not initiate the development of sunitinib-associated hypertension. J Hypertens. 2015; 33(10): 2075–2082.
    CrossRefPubMed
  78. Chintalgattu V, Rees ML, Culver JC, et al. Coronary microvascular pericytes are the cellular target of sunitinib malate-induced cardiotoxicity. Sci Transl Med. 2013; 5(187): 187ra69.
    CrossRefPubMed
  79. Lindahl P, Betsholtz C, Lindahl P, et al. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science. 1997; 277(5323): 242–245.
    CrossRefPubMed
  80. Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer. 2007; 7(5): 332–344.
    CrossRefPubMed
  81. Ushio-fukai M, Griendling KK, Becker PL, et al. Ionizing Radiation Accelerates Aortic Lesion Formation in Fat-Fed Mice via SOD-Inhibitable Processes. Arter Thromb Vasc Biol. 2014(February): 1387–1393.
  82. Dunsmore LD, LoPonte MA, Dunsmore RA. Radiation-induced coronary artery disease. J Am Coll Cardiol. 1986; 8(1): 239–244.
    CrossRefPubMed
  83. Hashmonai M, Elami A, Kuten A, et al. Subclavian artery occlusion after radiotherapy for carcinoma of the breast. Cancer. 1988; 61(10): 2015–2018, doi: 10.1002/1097-0142(19880515)61:10<2015::aid-cncr2820611014>3.0.co;2-z.
    PubMed
  84. Qi F, Sugihara T, Hattori Y, et al. Functional and morphological damage of endothelium in rabbit ear artery following irradiation with cobalt60. Br J Pharmacol. 1998; 123(4): 653–660.
    CrossRefPubMed
  85. Hull MC, Morris CG, Pepine CJ, et al. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. JAMA. 2003; 290(21): 2831–2837.
    CrossRefPubMed
  86. Campen CJ, Kranick SM, Kasner SE, et al. Cranial irradiation increases risk of stroke in pediatric brain tumor survivors. Stroke. 2012; 43(11): 3035–3040.
    CrossRefPubMed
  87. Brant-Zawadzki M, Anderson M, DeArmond SJ, et al. Radiation-induced large intracranial vessel occlusive vasculopathy. AJR Am J Roentgenol. 1980; 134(1): 51–55.
    CrossRefPubMed
  88. Beckman JA, Thakore A, Kalinowski BH, et al. Radiation therapy impairs endothelium-dependent vasodilation in humans. J Am Coll Cardiol. 2001; 37(3): 761–765.
    CrossRefPubMed
  89. Meeske KA, Siegel SE, Gilsanz V, et al. Premature carotid artery disease in pediatric cancer survivors treated with neck irradiation. Pediatr Blood Cancer. 2009; 53(4): 615–621.
    CrossRefPubMed
  90. Park KH, Park WJ. Endothelial Dysfunction: Clinical Implications in Cardiovascular Disease and Therapeutic Approaches. J Korean Med Sci. 2015; 30(9): 1213–1225.
    CrossRefPubMed
  91. Jones LW, Fels DR, West M, et al. Modulation of circulating angiogenic factors and tumor biology by aerobic training in breast cancer patients receiving neoadjuvant chemotherapy. Cancer Prev Res (Phila). 2013; 6(9): 925–937.
    CrossRefPubMed
  92. Cadeddu C, Mercurio V, Spallarossa P, et al. Preventing antiblastic drug-related cardiomyopathy: old and new therapeutic strategies. J Cardiovasc Med (Hagerstown). 2016; 17 Suppl 1: S64–S75.
    CrossRefPubMed
  93. Stojanović M, Radenković M. Vitamin D versus placebo in improvement of endothelial dysfunction: a meta-analysis of randomized clinical trials. Cardiovasc Ther. 2015; 33(3): 145–154.
    CrossRefPubMed
  94. Mantell DJ, Owens PE, Bundred NJ, et al. 1 alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res. 2000; 87(3): 214–220.
    CrossRefPubMed
  95. Heitzer T, Ylä Herttuala S, Wild E, et al. Effect of vitamin E on endothelial vasodilator function in patients with hypercholesterolemia, chronic smoking or both. J Am Coll Cardiol. 1999; 33(2): 499–505.
    CrossRefPubMed
  96. Keaney J, Vita J. Atherosclerosis, oxidative stress, and antioxidant protection in endothelium-derived relaxing factor action. Prog Cardiovas Dis. 1995; 38(2): 129–154.
    CrossRef
  97. Frcpe KY. Vitamin E in cardiovascular disease: has the die been cast? Asia Pacific J Clin Nutr. 2002; 11: 443–447.
  98. Hindler K, Cleeland CS, Rivera E, et al. The role of statins in cancer therapy. Oncologist. 2006; 11(3): 306–315.
    CrossRefPubMed
  99. Cardinale D, Bacchiani G, Beggiato M, et al. Strategies to prevent and treat cardiovascular risk in cancer patients. Semin Oncol. 2013; 40(2): 186–198.
    CrossRefPubMed
  100. Kalinowski L, Dobrucki LW, Szczepanska-Konkel M, et al. Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action. Circulation. 2003; 107(21): 2747–2752.
    CrossRefPubMed
  101. Rajagopalan S, Harrison DG. Reversing endothelial dysfunction with ACE inhibitors. A new trend. Circulation. 1996; 94(3): 240–243.
    PubMed
  102. Thakur A, Witteles RM. Cancer therapy-induced left ventricular dysfunction: interventions and prognosis. J Card Fail. 2014; 20(3): 155–158.
    CrossRefPubMed
  103. Abdel-Rahman O, Alorabi M. Use of angiotensin-converting enzyme inhibitors in the prophylaxis of anthracycline or trastuzumab-related cardiac dysfunction: preclinical and clinical considerations. Expert Rev Anticancer Ther. 2015; 15(7): 829–837.
    CrossRefPubMed
  104. Li X. ; 21(6): 1375–1383.
  105. Hartmann JT, Kollmannsberger C, Kanz L, et al. Platinum organ toxicity and possible prevention in patients with testicular cancer. Int J Cancer. 1999; 83(6): 866–869, doi: 10.1002/(sici)1097-0215(19991210)83:6<866::aid-ijc34>3.0.co;2-9.
    PubMed
  106. Räsänen M, Degerman J, Nissinen TA, et al. VEGF-B gene therapy inhibits doxorubicin-induced cardiotoxicity by endothelial protection. Proc Natl Acad Sci U S A. 2016; 113(46): 13144–13149.
    CrossRefPubMed

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Oncology in Clinical Practice

About Via Medica Advertising
Bookstore (Ikamed) TVMed
News
Copyright © 2023 Via Medica Regulations Cookie policy Privacy policy Legal Notice